MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Cytokinetics Inc

Abierto

SectorSalud

40.09 0.1

Resumen

Variación precio

24h

Actual

Mínimo

39.01

Máximo

40.45

Métricas clave

By Trading Economics

Ingresos

11M

-150M

Ventas

16M

17M

BPA

-1.26

Margen de beneficio

-886.276

Empleados

498

EBITDA

13M

-125M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+116.74% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.3B

4.5B

Apertura anterior

39.99

Cierre anterior

40.09

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Cytokinetics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2024, 15:26 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

11 abr 2025, 09:30 UTC

Principales Noticias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Comparación entre iguales

Cambio de precio

Cytokinetics Inc Esperado

Precio Objetivo

By TipRanks

116.74% repunte

Estimación a 12 meses

Media 82.36 USD  116.74%

Máximo 120 USD

Mínimo 54 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cytokinetics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

17

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

37.85 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.